Skip to main content

Advertisement

SpringerLink
Log in

Quality of life after treatment for prostate cancer

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Quality of life is a major concern of patients when they are choosing treatment for prostate cancer. Health-related quality of life is a patient-centered variable from the field of health services research that can be measured in a valid and reliable manner. Using standardized questionnaires specifically developed to capture health-related quality of life data in men with prostate cancer, the effect of treatments on patients’ quality of life can be studied. Patients with localized disease who are undergoing radical prostatectomy tend to have more sexual and urinary dysfunction than men undergoing external beam radiation therapy, although both groups have more impairment in these areas than agematched controls. Men undergoing external beam radiation therapy have worse bowel function and more urinary distress from irritative voiding symptoms than men undergoing radical prostatectomy or age-matched controls. Recent studies of men undergoing interstitial brachytherapy indicate that these patients have less urinary leakage than those who undergo radical prostatectomy, but experience considerably more irritating voiding symptoms, which often profoundly affect their quality of life. Better information regarding the potential impact of prostate cancer treatment on quality of life will improve medical decision-making.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Jemal A, Murray T, Samuels A, et al.: Cancer statistics: 2003. CA Cancer J Clin 2003, 53:5–26.

    Article  PubMed  Google Scholar 

  2. Klein EA: Radiation therapy versus radical prostatectomy in the PSA era: a urologist’s view. Semin Radiat Oncol 1998, 8:87–94.

    Article  PubMed  CAS  Google Scholar 

  3. Holmboe ES, Concato J: Treatment decisions for localized prostate cancer: asking men what’s important. J Gen Int Med 2000, 15:694–701.

    Article  CAS  Google Scholar 

  4. Schellhammer P, Cockett A, Boccon-Gibod L, et al.: Assessment of endpoints for clinical trials for localized prostate cancer. Urology 1997, 49:27–38.

    Article  PubMed  CAS  Google Scholar 

  5. Patrick DL, Erickson P: Assessing health-related quality of life for clinical decision-making. In Quality of Life Assessment: Key Issues in the 1990s. Edited by Walker SR, Rosser RM. Dordrecht: Kluwer Academic Publishers; 1993:19.

    Google Scholar 

  6. Litwin MS, Lubeck DP, Henning JM, Carroll PR: Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol 1998, 159:1988–1992.

    Article  PubMed  CAS  Google Scholar 

  7. Wilson IB, Cleary PD: Linking clinical variables with healthrelated quality of life: a conceptual model of patient outcomes. JAMA 1995, 273:59–65.

    Article  PubMed  CAS  Google Scholar 

  8. Penson DF, Latini DM, Lubeck DP, et al.: Is quality of life different for men with erectile dysfunction and prostate cancer compared to men with erectile dysfunction due to other causes? Results from the EXCEED Data Base. J Urol 2003, 169:1458–1461.

    Article  PubMed  Google Scholar 

  9. Shabsigh R, Klein LT, Seidman S, et al.: Increased incidence of depressive symptoms in men with erectile dysfunction. Urology 1998, 52:848–852.

    Article  PubMed  CAS  Google Scholar 

  10. Litwin MS, Hays RD, Fink A, et al.: The UCLA Prostate Cancer Index: development, reliability, and validity of a healthrelated quality of life measure. Med Care 1998, 36:1002–1012.

    Article  PubMed  CAS  Google Scholar 

  11. Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I: conceptual framework and item selection. Med Care 1992, 30:473–483.

    Article  PubMed  Google Scholar 

  12. Wei JT, Dunn RL, Litwin MS, et al.: Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000, 56:899–905.

    Article  PubMed  CAS  Google Scholar 

  13. Ware J Jr, Kosinski M, Keller SD: A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996, 34:220–233.

    Article  PubMed  Google Scholar 

  14. Aaronson NK, Ahmedzai S, Bergman B, et al.: The European Organization for Research and the Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:356–365.

    Article  Google Scholar 

  15. Borghede G, Karlsson J, Sullivan M: Quality of life in patients with prostatic cancer: results from a Swedish population study. J Urol 1997, 158:1477–1485.

    Article  PubMed  CAS  Google Scholar 

  16. Albertsen PC, Aaronson NK, Muller MJ, et al.: Health-related quality of life among patients with metastatic prostate cancer. Urology 1997, 49:207–216.

    Article  PubMed  CAS  Google Scholar 

  17. Esper P, Mo F, Chodak G, et al.: Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997, 50:920–928.

    Article  PubMed  CAS  Google Scholar 

  18. Messing EM, Manola J, Sarosdy M, et al.: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999, 341:1781–1788.

    Article  PubMed  CAS  Google Scholar 

  19. Anonymous: Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997, 79:235–246.

    Google Scholar 

  20. Herr HW, O’Sullivan M: Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 2000, 163:1743–1746.

    Article  PubMed  CAS  Google Scholar 

  21. Basaria S, Lieb J II, Tang AM, et al.: Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002, 56:779–786.

    Article  CAS  Google Scholar 

  22. Green HJ, Pakenham KI, Headley BC, Gardiner RA: Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring. Psychooncology 2002, 11:401–414.

    Article  PubMed  Google Scholar 

  23. Potosky AL, Reeve BB, Clegg LX, et al.: Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 2002, 94:430–437. One of the largest studies to explore the impact of androgen ablation therapy on health-related quality of life. A population-based cohort of prostate cancer survivors was used to demonstrate that hormone therapy is associated with worse quality of life.

    PubMed  Google Scholar 

  24. Litwin MS, Shpall AI, Dorey F, Nguyen TH: Quality-of-life outcomes in long-term survivors of advanced prostate cancer. Am J Clin Oncol 1998, 21:327–332.

    Article  PubMed  CAS  Google Scholar 

  25. Moinpour CM, Savage MJ, Troxel A, et al.: Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst 1998, 90:1537–1544.

    Article  PubMed  CAS  Google Scholar 

  26. Curran D, Fossa S, Aaronson N, et al.: Baseline quality of life of patients with advanced prostate cancer: European Organization for Research and Treatment of Cancer (EORTC), Genito-Urinary Tract Cancer Cooperative Group (GUT-CCG). Eur J Cancer 1997, 33:1809–1814.

    Article  PubMed  CAS  Google Scholar 

  27. Melmed GY, Kwan L, Reid K, Litwin MS: Quality of life at the end of life: trends in patients with metastatic prostate cancer. Urology 2002, 59:103–109.

    Article  PubMed  Google Scholar 

  28. Kantoff PW, Halabi S, Conaway M, et al.: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999, 17:2506–2513.

    PubMed  CAS  Google Scholar 

  29. Osoba D, Tannock IF, Ernst DS, Neville AJ: Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999, 17:1654–1663.

    PubMed  CAS  Google Scholar 

  30. Stanford JL, Stephenson RA, Coyle LM, et al.:Prostate Cancer Trends 1973–1995, SEER Program. Bethesda: National Cancer Institute; 1999.

    Google Scholar 

  31. Bacon CG, Giovannucci E, Testa M, et al.: The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients. Cancer 2002, 94:862–871.

    Article  PubMed  Google Scholar 

  32. Penson DF, Feng Z, Kuniyuki A, et al.: General quality of life 2 years following treatment for prostate cancer: What influences outcomes? Results from the Prostate Cancer Outcomes Study. J Clin Oncol 2003, 21:1147–1154.

    Article  PubMed  Google Scholar 

  33. Steineck G, Helgesen F, Adolfsson J, et al.: Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002, 347:790–796.

    Article  PubMed  Google Scholar 

  34. Stanford JL, Feng Z, Hamilton AS, et al.: Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000, 283:354–360. The authors use the PCOS, a population-based cohort, to explore quality of life outcomes after radical prostatectomy. Unlike other studies that tend to use patients from a single center, this report gives us a better understanding of what occurs after prostate cancer surgery in the community among unselected patients.

    Article  PubMed  CAS  Google Scholar 

  35. Steiner MS: Current results and patient selection for nervesparing radical retropubic prostatectomy. Semin Urol Oncol 1995, 13:204–214.

    PubMed  CAS  Google Scholar 

  36. Kao T, Cruess D, Garner D, et al.: Multicenter patient selfreporting questionnaire on impotence, incontinence and stricture after radical prostectomy. J Urol 2000, 163:858–864.

    Article  PubMed  CAS  Google Scholar 

  37. Murphy G, Mettlin C, Menck H, et al.: National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J Urol 1994, 152:1817–1819.

    PubMed  CAS  Google Scholar 

  38. Talcott JA, Rieker P, Propert KJ, et al.: Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. J Natl Cancer Inst 1997, 89:1117–1123.

    Article  PubMed  CAS  Google Scholar 

  39. Litwin MS, Flanders SC, Pasta DJ, et al.: Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 1999, 54:503–508.

    Article  PubMed  CAS  Google Scholar 

  40. Lubeck DP, Litwin MS, Henning JM, et al.: Changes in healthrelated quality of life in the first year after treatment for prostate cancer: results from CaPSURE. Urology 1999, 53:180–186.

    Article  PubMed  CAS  Google Scholar 

  41. Shrader-Bogen CL, Kjellberg JL, McPherson CP, Murray CL:Quality of life and treatment outcomes: prostate carcinoma patients’ perspectives after prostatectomy or radiation therapy. Cancer 1997, 79:1977–1786.

    Article  PubMed  CAS  Google Scholar 

  42. Herr HW: Quality of life of incontinent men after radical prostatectomy. J Urol 1994, 151:652–654.

    PubMed  CAS  Google Scholar 

  43. Dale W, Campbell T, Ignacio L, et al.: Self-assessed healthrelated quality of life in men being treated for prostate cancer with radiotherapy: instrument validation and its relation to patient-assessed bother of symptoms. Urology 1999, 53:359–366.

    Article  PubMed  CAS  Google Scholar 

  44. Fransson P, Widmark A: Late side effects unchanged 4-8 years after radiotherapy for prostate carcinoma: a comparison with age-matched controls. Cancer 1999, 85:678–88. The strength of this study lies in its relatively long follow-up, which is unusual in the quality-of-life literature. It demonstrates that men who undergo EBRT can expect to have worsening of quality of life up to 4 years after treatment, but that outcomes remain stable from year 4 to year 8.

    Article  PubMed  CAS  Google Scholar 

  45. Franklin CI, Parker CA, Morton KM: Late effects of radiation therapy for prostate carcinoma: the patient’s perspective of bladder, bowel and sexual morbidity. Australas Radiol 1998, 42:58–65.

    PubMed  CAS  Google Scholar 

  46. Reddy SM, Ruby J, Wallace M, Forman JD: Patient self-assessment of complications and quality of life after conformal neutron and photon irradiation for localized prostate cancer. Radiat Oncol Investig 1997, 5:252–256.

    Article  PubMed  CAS  Google Scholar 

  47. Mantz CA, Nautiyal J, Awan A, et al.: Potency preservation following conformal radiotherapy for localized prostate cancer: impact of neoadjuvant androgen blockade, treatment technique, and patient-related factors. Cancer J Sci Am 1999, 5:230–236.

    PubMed  CAS  Google Scholar 

  48. Fowler FJ Jr, Barry MJ, Lu-Yao G, et al.: Outcomes of externalbeam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas. J Clin Oncol 1996, 14:2258–2265.

    PubMed  Google Scholar 

  49. Helgason AR, Adolfsson J, Dickman P, et al.: Waning sexual function: the most important disease-specific distress for patients with prostate cancer. Br J Cancer 1996, 73:1417–1421.

    PubMed  CAS  Google Scholar 

  50. Widmark A, Fransson P, Tavelin B: Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population. Cancer 1994, 74:2520–2532.

    Article  PubMed  CAS  Google Scholar 

  51. Litwin MS, Hays RD, Fink A, et al.: Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995, 273:129–135. One of the first studies to use a validated HRQOL instrument to assess outcomes in localized prostate cancer. This cross-sectional study demonstrates that men undergoing radiotherapy or surgery can expect to have worse disease-specific quality of life than age-matched control subjects.

    Article  PubMed  CAS  Google Scholar 

  52. Crook J, Esche B, Futter N: Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function: the patient’s perspective. Urology 1996, 47:387–394.

    Article  PubMed  CAS  Google Scholar 

  53. Lee WR, McQuellon RP, Case LD, et al.: Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer. J Urol 1999, 162:403–406.

    Article  PubMed  CAS  Google Scholar 

  54. Lee WR, McQuellon RP, Harris-Henderson K, et al.: A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2000, 46:77–81. This study is among the few that provide longitudinal quality-of-life data for patients undergoing brachytherapy. It documents that, although most patients experience irritative voiding symptoms during the first 3 months after treatment, these symptoms resolve in most patients during 1 year of therapy.

    Article  PubMed  CAS  Google Scholar 

  55. Talcott JA, Clark JA, Stark PC, Mitchell SP: Long-term treatment-related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. J Urol 2001, 166:494–499. A highly controversial report demonstrating that many patients undergoing brachytherapy experience urinary incontinence. Although critics of this study note that the patients examined were treated early in the “brachytherapy era” and that improvements in technique have now lessened the incontinence rate considerably, the study provides evidence that patients must consider the risk of incontinence (urge and stress) when choosing brachytherapy.

    Article  PubMed  CAS  Google Scholar 

  56. Arterbery VE, Frazier A, Dalmia P, et al.: Quality of life after permanent prostate implant. Semin Surg Oncol 1997, 13:461–464.

    Article  PubMed  CAS  Google Scholar 

  57. Hollenbeck BK, Dunn RL, Wei JT, et al.: Neoadjuvant hormonal therapy and older age are associated with adverse sexual health-related quality-of-life outcome after prostate brachytherapy. Urology 2002, 59:480–484.

    Article  PubMed  Google Scholar 

  58. Joly F, Brune D, Couette JE, et al.: Health-related quality of life and sequelae in patients treated with brachytherapy and external beam irradiation for localized prostate cancer. Ann Oncol 1998, 9:751–757.

    Article  PubMed  CAS  Google Scholar 

  59. Brandeis J, Litwin M, Burnison C, Reiter R: Quality of life outcomes after brachytherapy for early stage prostate cancer. J Urol 2000, 163:851–857.

    Article  PubMed  CAS  Google Scholar 

  60. Merrick GS, Butler WM, Galbreath RW, et al.: Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002, 52:893–902.

    Article  PubMed  Google Scholar 

  61. Akakura K, Isaka S, Akimoto S, et al.: Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities. Urology 1999, 54:313–318.

    Article  PubMed  CAS  Google Scholar 

  62. Potosky AL, Legler J, Albertsen PC, et al.: Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000, 92:1582–1592. Another report from the PCOS, this analysis directly compared outcomes in men undergoing radical prostatectomy and radiotherapy. Although the study has a number of limitations, it demonstrates that 2-year disease-specific HRQOL is better after radiotherapy for most patients.

    Article  PubMed  CAS  Google Scholar 

  63. McCammon KA, Kolm P, Main B, Schellhammer PF: Comparative quality-of-life analysis after radical prostatectomy or external beam radiation for localized prostate cancer. Urology 1999, 54:509–516.

    Article  PubMed  CAS  Google Scholar 

  64. Lim AJ, Brandon AH, Fiedler J, et al.: Quality of life: radical prostatectomy versus radiation therapy for prostate cancer. J Urol 1995, 154:1420–1425.

    Article  PubMed  CAS  Google Scholar 

  65. Wei JT, Dunn RL, Sandler HM, et al.: Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 2002, 20:557–566. One of the few studies to use a validated instrument to directly compare HRQOL outcomes among surgery, EBRT, and brachytherapy. The authors demonstrate that HRQOL outcomes after brachytherapy are considerably worse than previously reported and, in some instances, worse than surgery and EBRT. The study also documents that sexual function is poor after all three forms of treatment.

    Article  PubMed  Google Scholar 

  66. Litwin MS, Pasta DJ, Yu J, et al.: Urinary function and bother after radical prostatectomy or radiation for prostate cancer: a longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol 2000, 164:1973–1977.

    Article  PubMed  CAS  Google Scholar 

  67. Krupski T, Petroni G, Bissonette E, Theodorescu D: Quality-oflife comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinical localized prostate cancer. Urology 2000, 55:736–742.

    Article  PubMed  CAS  Google Scholar 

  68. Bacon CG, Giovannucci E, Testa M, Kawachi I: The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol 2001, 166:1804–1810.

    Article  PubMed  CAS  Google Scholar 

  69. Davis JW, Kuban DA, Lynch DF, Schellhammer PF: Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J Urol 2001, 166:962–963.

    Article  Google Scholar 

  70. Galbreath ME, Ramirez JM, Pedro LW: Quality of life, health outcomes, and identity for patients with prostate cancer in five different treatment groups. Oncol Nurs Forum 2001, 28:551–560.

    Google Scholar 

  71. Madalinska JB, Essink-Bot ML, de Koning HJ, et al.: Healthrelated quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment. Prostate 2001, 46:87–97.

    Article  PubMed  CAS  Google Scholar 

  72. Schapira MM, Lawrence WF, Katz DA, et al.: Effect of treatment on quality of life among men with clinically localized prostate cancer. Med Care 2001, 39:243–253.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Urology and Health Services, David Geffen School of Medicine and School of Public Health, University of California, Los Angeles 66-121CHS, Box 951738, 90095-1738, Los Angeles, CA, USA

    Mark S. Litwin MD, MPH

Authors
  1. David F. Penson MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark S. Litwin MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Penson, D.F., Litwin, M.S. Quality of life after treatment for prostate cancer. Curr Urol Rep 4, 185–195 (2003). https://doi.org/10.1007/s11934-003-0068-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-003-0068-1

Keywords

Search

Navigation